| 3.015 0.285 (10.44%) | 05-16 13:59 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 3.55  |
1-year : | 4.14 |
| Resists | First : | 3.03 |
Second : | 3.55 |
| Pivot price | 2.53 |
|||
| Supports | First : | 2.36 |
Second : | 1.95 |
| MAs | MA(5) : | 2.67 |
MA(20) : | 2.49 |
| MA(100) : | 2.91  |
MA(250) : | 3.98 |
|
| MACD | MACD : | 0 |
Signal : | 0 |
| %K %D | K(14,3) : | 79.6 |
D(3) : | 72.5 |
| RSI | RSI(14): 64.1 |
|||
| 52-week | High : | 5.59 | Low : | 1.84 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and NEUTRAL in mid-long term.[ ACHV ] has closed above the upper band by 21.0%. If price is in a uptrend band; this upward trend in price might continue. However a short term pullback inside the band is likely.Bollinger Bands are 8% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 2.73 - 2.74 | 2.74 - 2.76 |
| Low: | 2.46 - 2.47 | 2.47 - 2.49 |
| Close: | 2.71 - 2.73 | 2.73 - 2.75 |
Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in Canada, the United States, and the United Kingdom. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain that reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.
Wed, 14 May 2025
Raymond James Financial Inc. Purchases New Position in Achieve Life Sciences, Inc. (NASDAQ:ACHV) - MarketBeat
Wed, 14 May 2025
Achieve Life Sciences, Inc. (NASDAQ:ACHV) Q1 2025 Earnings Call Transcript - Insider Monkey
Wed, 14 May 2025
Achieve Life Sciences Inc (ACHV) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
Wed, 14 May 2025
Achieve Life Sciences Inc (ACHV) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Tue, 13 May 2025
Transcript : Achieve Life Sciences, Inc., Q1 2025 Earnings Call, May 13, 2025 - marketscreener.com
Tue, 13 May 2025
ACHIEVE LIFE SCIENCES Earnings Results: $ACHV Reports Quarterly Earnings - Nasdaq
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 35 (M) |
| Shares Float | 29 (M) |
| Held by Insiders | 9.8 (%) |
| Held by Institutions | 46.9 (%) |
| Shares Short | 2,500 (K) |
| Shares Short P.Month | 3,030 (K) |
| EPS | -1.25 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0.6 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -84.2 % |
| Return on Equity (ttm) | -409.6 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.12 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -30 (M) |
| Levered Free Cash Flow | -18 (M) |
| PE Ratio | -2.43 |
| PEG Ratio | 0 |
| Price to Book value | 5.01 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.51 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|